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Abstract Drug-induced interstitial lung disease is a rare
condition attributed to several medications, including
antimicrobial agents such as amphotericin B, anti-inflam-
matory agents such as methotrexate, biologic agents such
as bevacizumab, and cardiovascular agents and
chemotherapeutic agents. We describe the case of a
73-year-old female who developed interstitial lung disease
following chronic use of nitrofurantoin for a urinary tract
infection (UTI). The patient was taking nitrofurantoin
100 mg capsules twice daily for approximately 3 years.
She presented to the hospital with complaints of a persis-
tent dry cough that started 2 years previously. Her chest
radiograph revealed bilateral reticular opacities and some
atelectasis. Computed tomography of the chest demon-
strated development of subpleural reticular opacities with
minimal honeycombing. The patient had a severe restric-
tive defect on her pulmonary function tests, with a signif-
icant reduction in her carbon monoxide diffusion capacity.
Multiple infectious disease and autoimmune tests were
negative. Utilizing the algorithm of Naranjo (score of 9), it
was determined that chronic use of nitrofurantoin was the
definite cause of the patient’s interstitial lung disease.
Nitrofurantoin was discontinued and she was treated with
oxygen and started on an oral steroid, both of which were
continued permanently once discharged. Upon discharge,
the patient was maintained on 5 L of oxygen at rest and
10 L of oxygen when ambulating. Unfortunately, her lung
disease ultimately resulted in her demise several months
after her diagnosis. This case report illustrates the impor-
tance of rapid recognition of drug-induced lung injuries
and discontinuation of the offending agent.
Key Points
Chronic use of nitrofurantoin can lead to pulmonary
complications such as interstitial lung disease.
Nitrofurantoin should be stopped upon the first sign
of lung injury.
Nitrofurantoin should only be considered if other
therapies have failed and suitable patient monitoring
is available.
Background
Drug-induced interstitial lung disease is a rare condition
attributed to several medications, including antimicrobial
agents such as amphotericin B, anti-inflammatory agents
such as methotrexate, biologic agents such as beva-
cizumab, and cardiovascular agents and chemotherapeutic
agents [1]. The current Infectious Diseases Society of
America and European Society of Microbiology and
Infectious Diseases guidelines recommend nitrofurantoin
as a first-line medication for the treatment of uncompli-
cated cystitis and suppression of recurrent urinary tract
infections (UTIs), a common problem prevalent in females
[2, 3]. The classic presentation of interstitial lung disease
usually occurs within 3–8 days of starting nitrofurantoin,
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but may occur a few hours to 4 weeks after the first dose
[4]. Confirmatory diagnosis is based on clinical imaging
and histopathology, documentation of drug exposure,
improvement after discontinuing the agent, and symptom
onset following a rechallenge with the offending agent
[5, 6]. We report a case of interstitial lung disease as a
result of chronic exposure to nitrofurantoin, as well as a
review of the current literature.
Case Report
In early 2015, a 73-year-old female presented for evaluation
of a persistent dry cough that started 2 years ago and had
progressively worsened with exertional dyspnea over the
past week. Her hypertensive medication, lisinopril, was
changed to valsartan several months ago, without any
improvement in her cough. Her past medical history was
remarkable for hypertension, chronic UTIs, hyperlipidemia,
and hypothyroidism. She had recurrent UTIs and was taking
nitrofurantoin 100 mg twice daily for approximately
3 years preceding the onset of symptoms. She had no pre-
vious lung disease, smoking history, or past work exposure.
On physical examination, the patient was afebrile and
appeared mildly distressed, fatigued, and short of breath,
with a non-productive cough. She denied any chest pain.
Her respiratory rate was 20 per minute, and she had a blood
pressure of 157/94 mmHg, pulse of 102 beats per minute,
and a hemoglobin oxygen saturation of 90 % on room air.
Laboratory studies revealed a white blood cell count of
8.82/mm3 (range 4.3–10.60), with no blood eosinophilia
present. Her chemistry panel was within the normal range.
The erythrocyte sedimentation rate was 18 mm/h (normal
range 0–29 mm/h for women) and d-dimer was\150 ng/
mL. She was euthyroid, and enzyme-linked immunosorbent
assay for human immunodeficiency virus was negative.
Antinuclear antibody, antineutrophil cytoplasmic antibody,
and rheumatoid factor were normal. The chest radiograph
revealed bilateral reticular opacities and some atelectasis
(Fig. 1), and computed tomography (CT) of the chest
demonstrated development of subpleural reticular opacities
with minimal honeycombing (Fig. 2). Pulmonary function
tests showed a severe restrictive defect (forced vital
capacity [FVC] 1.18 L, 36.6 % of predicted, forced expi-
ratory volume at 1 s [FEV1]/FVC was 95.2 %, FEV1
1.12 L, 45.2 % of predicted, suggestive of restriction) with
severely reduced carbon monoxide diffusion capacity
(DLCO 17.3 %, diffusing capacity corrected for alveolar
volume [DLCO/VA], 49.4 % predicted). The total lung
capacity (TLC) of 2.98 L was 53.5 % of predicted and
confirmed restriction, in addition to the residual volume
(RV) being 1.80 L, which was 78.9 % of predicted. Overall,
there was severely decreased lung capacity and decreased
diffusion capacity. Electrocardiograph and echocardiogra-
phy were normal, along with all other cardiology find-
ings. Nitrofurantoin-induced lung disease was suspected
with a differential diagnosis of pneumonia and pulmonary
embolism. Empiric community-acquired pneumonia treat-
ment was initiated with piperacillin-tazobactam 3.375 g
intravenously every 6 h, vancomycin 1.5 g intravenous
Fig. 1 Chest radiograph revealed bilateral reticular opacities and
some atelectasis
Fig. 2 High-resolution computed tomography of the chest in the
prone position showing development of subpleural reticular opacities
with minimal honeycombing
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piggy back every 12 h, and methylprednisolone 40 mg
intravenously every 6 h. The antibiotics were discontinued
on day 2. The day following admission (day 2), the patient
still experienced shortness of breath, mainly with activity,
and her oxygen saturation dropped to 50 % while she was
receiving 5 L of oxygen. She required 10 L of oxygen to
maintain saturation above 85 % while ambulating. Her
cough was now productive, with scanty whitish sputum, and
antibiotic therapy was de-escalated to levofloxacin 750 mg
daily as the patient was afebrile with a normal white blood
cell count. Methylprednisolone was discontinued on day 3
and the patient was started on prednisone 60 mg daily by
mouth. Nitrofurantoin was discontinued. On day 3, the
patient utilized 5 L of oxygen while lying in bed and 10 L
of oxygen when ambulating. She denied any fever or chest
pain overnight. There was no blood culture growth and the
sputum culture was indicative of normal upper respiratory
flora. She was maintained on 5 L of oxygen at rest and 10 L
of oxygen when ambulating, and was discharged the fol-
lowing day with 5 more days of levofloxacin therapy and a
taper regimen for prednisone, such that she would be on a
maintenance dose of 30 mg daily after tapering. Her
nitrofurantoin was switched to cephalexin 500 mg four
times daily for long-term prophylaxis. Months after, the
patient became septic secondary to pneumonia, which lead
to her demise.
Discussion
Since 1953, nitrofurantoin has been used for uncomplicated
UTIs with a low resistance. Nitrofurantoin works by
inhibiting aerobic energy metabolism, DNA synthesis,
RNA synthesis, cell wall synthesis, and protein synthesis. It
is active against gram-positive aerobes such as Staphylo-
coccus saprophyticus, and gram-negative aerobes such as
Escherichia coli [7]. The package insert for nitrofurantoin
specifically warns about pulmonary reactions, including,
but not limited to, diffuse interstitial pneumonitis and
pulmonary fibrosis [8].
There is no consensus explanation or description per-
taining to the mechanism of action of nitrofurantoin-in-
duced interstitial lung disease. Hypersensitivity to
nitrofurantoin is one of the proposed mechanisms of action
and is thought to be the cause of acute presentation of lung
damage [9–12]. It is theorized that the lymphocytes acti-
vated by nitrofurantoin facilitate the release of cytokines,
which result in lymphocytic alveolitis, or more commonly
known as extrinsic allergic alevolitis [10, 13]. As this is a
theorized hypersensitivity and inflammatory reaction, ster-
oid therapy may be considered. Other theorized mecha-
nisms of action include disruption in the balance of oxidants
and antioxidants in the lung, as well as direct damage to the
parenchymal cells of the lung. When the balance of oxidants
and antioxidants are disrupted, toxic products are formed,
which can cause interstitial lung fibrosis [9, 10, 14]. Direct
toxicity may be correlated with dose and as such would be
more applicable to the chronic presentation of lung damage;
however, to our knowledge, there have not been any studies
showing a direct correlation between dose of nitrofurantoin
and interstitial lung disease.
The variable clinical presentation of nitrofurantoin-in-
duced interstitial lung disease makes diagnosis difficult,
and thus withdrawal of the drug is oftentimes delayed.
Ideally, viral studies and tests for hypersensitivity pneu-
monitis should be performed; however, diagnosis of
interstitial lung disease secondary to nitrofurantoin use has
become more of a process of exclusion. Nitrofurantoin
interstitial lung disease can be categorized as acute or
chronic and, to date, has not been correlated with dose
dependence [15]. Acute manifestation is more prevalent
than chronic manifestation, and its presentation consists of
a maculopapular rash, fever, fatigue, arthralgia, dyspnea,
cough, and chest pain, and, in some cases pulmonary
edema. Eosinophilia in the serum or bronchoalveolar
lavage may also be present but is not indicative of an acute
manifestation as it may also be present in chronic mani-
festation [9, 12]. The onset of symptoms may occur within
hours to 2 weeks upon starting the drug. With acute pre-
sentation, the pulmonary function test may show a
restrictive flow with reduced diffusion capacity. The major
difference between acute and chronic is that the symptoms
will tend to dissipate in the former rather than the latter
once nitrofurantoin is discontinued [9, 11, 12].
Chronic presentation is infrequent and occurs in patients
who have been utilizing nitrofurantoin for at least 6 months or
more. It is interesting to note that prior acute reactions do not
potentiate the development of a chronic reaction [16, 17].
Chronic presentation occurs over weeks to years and consists
of a progressive dry cough and progressive dyspnea [18–20].
With chronic presentation, clubbing, inspiratory crepitations,
and bilateral interstitial infiltrates on a chest X-ray may be
present. Additionally, a restrictive flow with reduced diffu-
sion capacity may be seen on the pulmonary function test. Of
note, in chronic presentation there is marked honeycombing
of the lung(s) seen on high resolution CT scans [19, 20].
Our patient’s respiratory symptoms could have been
attributed to pulmonary congestion, indicating possible
heart failure. In addition, her prior use of lisinopril could
have been the cause of her cough; however, considering the
patient had been taking these medications for years, they
were ruled out as causative agents. Our patient presented
with more of a chronic presentation as she had prior
exposure to nitrofurantoin for more than 2 years.
There is a paucity of data to indicate gender as a risk
factor for drug-induced interstitial lung disease; however,
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in the literature, patients of older age have been shown to
be more susceptible to drug-induced interstitial lung dis-
ease. This may be attributed to the fact that as a person
ages, their renal function declines, and blood flow to the
liver and general circulation is decreased, in addition to
slowed metabolism [1, 21]. Our patient’s calculated crea-
tinine clearance was 50.7 mL/min and, according to the
product information for nitrofurantoin, use in creatinine
clearance\60 mL/min is contraindicated [22].
Based on the Naranjo algorithm [23], our patient had a
score of 9, indicating the interstitial lung disease was defi-
nitely caused by nitrofurantoin. This diagnosis is further
supported by clinical imaging, documentation of drug expo-
sure, and mild improvement after discontinuing nitrofuran-
toin. Treatment begins with discontinuation of nitrofurantoin,
which usually results in clinical improvement within 24 h,
with other findings such as chest radiograph opacities
requiring a longer period of time to resolve. The literature
suggests high-resolution CT is superior to chest radiography
and is valuable in detecting interstitial lung disease when
compared with the latter [6]. Depending on the clinical pre-
sentation of the patient, bronchodilators, oxygen, and short
bursts of steroids can be utilized to abate symptoms [16, 24].
With respect to our patient, prednisone was utilized as an
inpatient and then continued long-term as an outpatient.
With the rising resistance to fluoroquinolones and
trimethoprim/sulfamethoxazole, nitrofurantoin is more
commonly being considered for the treatment of recurrent
UTIs. However, the link between the rare but serious
adverse effect between nitrofurantoin and interstitial lung
disease is well-documented in the literature [5, 25–29] and
should be taken into account when selecting a chronic
prophylactic regimen. Studies have shown nitrofurantoin to
be clinically efficacious to ciprofloxacin, third-generation
cephalosporins, and amoxicillin for the treatment of UTIs
[2, 7, 30]. Thus, there are safer alternatives that can be
considered and these should be tried prior to initiating a
patient on nitrofurantoin, taking into consideration local
institution resistance rates.
Conclusions
Nitrofurantoin-induced interstitial lung disease is a well-
documented phenomenon that often goes misdiagnosed due
to its presentation, and is often treated as pneumonia,
myocardial infarction, heart failure, and even pulmonary
embolism. It is important to realize the adverse effects of
nitrofurantoin and their clinical presentation, and carefully
evaluate the risk versus benefit prior to initiating treatment.
Patients receiving nitrofurantoin long-term should be
assessed periodically. In the event a patient is prescribed
nitrofurantoin, the pharmacist plays an integral role in
counseling patients and stressing the importance of
reporting breathing difficulty or unusual symptoms to their
prescriber as soon as possible.
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